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ABSTRACT
Acute kidney injury (AKI) occurs frequently after nonmyeloablative hematopoietic cell transplantation (HCT).
The severity of AKI after nonmyeloablative HCT has association with short-termmortality. However, the long-
term effect of AKI on survival after nonmyeloablative HCT is not known.We performed a retrospective analysis
of patients who underwent an HLAmatched nonmyeloablative HCT between 1997 and 2006. Patients were fol-
lowed for a median of 36 (range: 3-99) months. AKI occurring up to day 100 was defined as a.2-fold increase in
serum creatinine or requirement of dialysis. Of the 358 patients whowere included in the analysis, 200 (56%) had
AKI, 158 (44%) had no AKI. Overall, 158 patients (43%) died during follow-up. After controlling for potential
confounders, the adjusted hazard ratio for overall mortality associated with AKI was 1.57 (95 % confidence in-
terval [CI] 1.2-2.3; P 5 .0006). The adjusted hazards ratio of nonrelapse mortality (NRM) associated with AKI
was 1.72 (95% CI 0.9-3.1; P5 .07). AKI is an independent predictor of overall mortality after nonmyeloablative
HCT.This finding reiterates the importance of identifying preventative strategies in nonmyeloablativeHCT for
attenuating incidence and severity of AKI.
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Allogeneic hematopoietic cell transplantation
(HCT) can be curative for advanced hematologic and
nonhematologic malignancies. Myeloablative alloge-
neic HCT involves the use of high-dose chemotherapy
and/or radiotherapy regimens to eradicate the under-
lying disease, and the allograft serves to rescue the
patient from pancytopenia induced by the treatment.
The major limitation of this procedure is the high
degree of toxicity associated with the myeloablative
conditioning regimen, which has restricted the use of
this procedure to younger otherwise fit patients [1,2].
Nonmyeloablative HCT involves a lower dose condi-
tioning regimen, and can be offered to patients over
the age of 60 years or to patients with medical comor-
bidities. Although the nonmyeloablative HCT
procedure has been in use for only a decade, resultsdemonstrate less toxicity and similar efficacy in some
malignancies when compared to conventional myeloa-
blative HCT [3,4]. The indications and use of
nonmyeloablative HCT are increasing, but some
problems still persist. For example, transplant-related
morbidity and mortality remains a significant obstacle
to achieving maximal benefits that can be obtained
from HCT. Transplant-related organ dysfunction
constitutes a major portion of transplant-related
complications that contribute to poor outcomes after
HCT. Renal failure has been recognized as a frequent
complication after allogeneic HCT [5,6].
We have previously described the incidence,
features, and severity of acute kidney injury (AKI) in
both myeloablative and nonmyeloablative HCT
[7,8]. In nonmyeloablative HCT, AKI occurs in about
40% of the patients and in the first 100 days of HCT.309
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after nonmyeloablative HCT at 6 months and 1 year
has a linear association with severity of AKI [8]. In
addition, AKI occurring in the first 100 days after
nonmyeloablative HCT is associated with the devel-
opment of chronic kidney disease (CKD) at 6 months
[9]. However, the long-term impact of AKI on survival
after nonmyeloablative HCT beyond 1 year is not
known.
AKI is traditionally thought to be a fully reversible
process in a majority of cases, and thus there is no clin-
ical follow-up after recovery. However, recent studies
demonstrate that AKI is associated with premature
death on long-term follow-up following cardiac
surgery, acute myocardial infarction, and in critically
ill patients [10-12]. Although studies have shown that
AKI independently predicts short-term mortality after
allogeneic HCT [13], it is unknown if AKI indepen-
dently influences the long-term outcomes in nonmye-
loablative allogeneic HCT. It is likely that AKI
contributes to development of CKD and hypertension,
which are well-known cardiovascular risk factors and
affect long-term mortality. We thus hypothesized
that AKI is an independent predictor of long-term
mortality after nonmyeloablative HCT. We explored
this question in a cohort of patients that underwent
nonmyeloablative HCT between 1997 and 2006 in
an academic institution.
METHODS
Patients
Weperformed a retrospective analysis of data from
409 patients who underwent HLA-matched related
and unrelated nonmyeloablative HCT for hemato-
logic malignancy from December 1997 to June 2006
at the Fred Hutchinson Cancer Research Center in
Seattle. As AKI is known to occur in the first 100
days after nonmyeloablative HCT and as we were
looking for association between AKI and long-term
mortality, patients who survived \100 days after
nonmyeloablative HCT were excluded. Patients al-
ready on maintenance dialysis prior to HCT were
also excluded, leaving 358 patients available for final
analysis.
Nonmyeloablative Procedure
Patients were considered for nonmyeloablative
HCT if they had hematologic malignancies and were
either too old or had comorbidities that would make
them ineligible for myeloablative HCT, or refused
myeloablative HCT. The conditioning regimen
consisted of 2 Gy of total body irradiation (TBI) either
given alone or combined with fludarabine 30 mg/m2
for the preceding 3 days. The patients received hema-
topoietic cell grafts from HLA-matched related or
unrelated donors derived from either peripheral bloodcells or bone marrow. Other details of the procedure
such as antibiotic prophylaxis are described elsewhere
[14]. Patients were administeredmycophenolate mofe-
til (MMF) and cyclosporine (CSP) for graft-versus-
host disease (GVHD) prophylaxis. MMFwas adminis-
tered orally at 15 mg/kg twice daily from days 0 to127
in related recipients, whereas in unrelated recipients,
MMF was administered twice a day or three times
a day through day 40. CSP was administered at 6.25
mg/kg twice a day orally from day 23, with trough
levels targeted at 500 to 600 ng/mL. CSP was gradu-
ally tapered from day 135 until day 1180 according
to evolving GVHD prohylaxis protocols. GVHD
treatment consisted of methylprednisolone and
resumption of CSP, if already tapered.
Variables
All the variables used for this study were collected
in a database maintained at Fred Hutchinson Cancer
Research Center.
Independent Variables
Renal function was assessed by serum creatinine
concentration and an estimated glomerular filtration
rate (GFR) calculated by the modified diet in renal
disease (MDRD) equation (GFR [mL/min per 1.73
m2] 5 186 *PCr
21.154 *age20.203 *1.212 if black,
*0.742 if female) [15]. AKI was defined as .2-fold
increase in serum creatinine or the requirement of
dialysis. Comorbidities were assessed retrospectively
by comprehensive review of medical records and
computer database systems. Scores were assigned by
a single investigator (M.L.S.) using the HCT-specific
comorbidity index (HCT-comorbidity index). The
HCT-comorbidity index was recently developed to
be appropriate for patients diagnosed with hemato-
logic malignancies and offered allogeneic HCT. The
HCT-comorbidity index included parameters for car-
diac, pulmonary, hepatic, gastrointestinal, and renal
function tests to allow for sensitive detection of
subclinical organ impairments. It has been validated
and shown to be strongly associated with nonrelapse
mortality (NRM) [16]. Each comorbidity, including
CKD, was assigned a specific number of points, and
the patient’s overall HCT-comorbidity index score
represented the sum of all points assigned. Malignan-
cies were divided into indolent and aggressive
categories. Indolent diseases included chronicmyelog-
enous leukemia (CML) in the first chronic phase, acute
leukemia in the first complete remission, chronic
lymphocytic leukemia (CLL), low-grade non-Hodg-
kin lymphoma (NHL), multiple myeloma (MM), and
myelodysplasia with refractory anemia or refractory
anemia with ringed sideroblasts. Aggressive categories
included more advanced CML, acute leukemia, and
MDS added to other hematologic malignancies
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defined as previously described [19].
Dependent Variables
All-cause mortality on follow-up was our primary
endpoint. Mortality was further classified as NRM
and relapse mortality. NRM was defined as death
occurring after HCT in the absence of progression
or relapse of malignancy. NRM was caused by trans-
plant-related complications in the majority of causes.
NRM and clinically extensive chronic GVHD
(cGVHD) were secondary endpoints. Diagnosis and
grading of GVHDwere performed according to estab-
lished criteria [20].
Study Conduct
This study was approved by the institutional re-
view boards of the Fred Hutchison Cancer Research
Center and Yale University School of Medicine.
Statistical Analysis
Patients were divided into 2 groups based on the
development of AKI. For univariate analysis continu-
ous variables were analyzed using the t-test or theWil-
coxon rank-sum test. Categoric variables were
expressed as proportions and compared with the chi-
squared test. Survival curves were estimated by the
Kaplan-Meier method; cumulative incidence curves
were estimated for NRM. Cox regression was used
to estimate adjusted hazard ratios in multivariate anal-
ysis of overall mortality, NRM, and cGVHD. Relapse
or progression was treated as a competing risk for
analysis of NRM; death was treated as a competing
risk for analysis of cGVHD.
RESULTS
There were 409 patients who underwent an HLA-
matched nonmyeloablative HCT for a hematologic
malignancy from December 1997 to June 2006.
Forty-seven (11%) patients were excluded from the
analysis as they died before day 100. Three patients
(0.7%) were excluded because of being on dialysis
pre transplant and 1 patient without baseline creati-
nine was excluded, leaving 358 patients available for
analysis after exclusion criteria.
Occurrence of AKI in Nonmyeloablative HCT
Recipients
Of the 358 patients who were included in the anal-
ysis, 200 (56%) had AKI and 158 patients were classi-
fied as no AKI. In the 47 patients who were excluded
because of death before day 100, 37 had AKI, and 10
had no AKI. Overall 10 (2.4%) patients had AKI, re-
quiring dialysis; 8 of them died before day 100 and
were not included in the analysis. Thus, only 2 patients
who survived dialysis were in the final AKI group. Themedian time to development of AKI was 22 days
(range: 3-99 days).
We assessed the recovery of renal function after
AKI by using the minimum reported serum creatinine
values between the first determination of AKI and day
100. Of the patients who developed AKI, 13% (n5 24)
had persistent increase in serum creatinine, 50% (n 5
100) had creatinine\1.2 times the baseline, and 37%
(n 5 74) had serum creatinine between 1.2 and 1.5
times the baseline value. Two patients had no creati-
nine measurements between the initial determination
of AKI and day 100. The patients with persistent in-
crease in creatinine did not have a higher risk of mor-
tality when compared with patients who returned to
baseline after AKI.
Baseline Demographics
Patients with AKI were more often males, had
higher GFR at baseline, were more often CMV1,
and more frequently received peripheral blood stem
cells (PBSC) as a stem cell source compared to patients
without AKI. Patients without AKI had received flu-
darabine more often and received more frequently
grafts from unrelated donors (Table 1).
Effect of AKI on Long-Term Mortality
Overall, 158 patients (43%) died during follow-up.
The median follow-up of surviving patients was 36
months (range: 3-99 months). Out of the 158 patients
that died, 62 (39%) of the deaths were because of
NRM. The major causes of mortality in the nonre-
lapse group were cGVHD (25%), pulmonary compli-
cations (22%), and infectious complications (20%).
Kaplan-Meier curves demonstrate the differences in
long-term mortality and NRM between patients who
did and did not develop AKI (Figures 1 and 2).
The multivariate analysis associating grade 2 AKI
with overall mortality, NRM, and clinical extensive
cGVHD is shown in Table 2. Proportional hazards re-
gression models were adjusted for potential con-
founders including sex, sex mismatch, age, disease
type, HCT-comorbidity index scores, presence of
CKD (defined as baseline GFR\ 60), CMV status,
stem cell source, conditioning, donor type, prior acute
GVHD (aGVDH), and prior cGVHD. The unad-
justed hazard ratio for overall mortality associated
with AKI was 1.42 (95% confidence interval [CI]
1.0-2.0; P 5 .03). After controlling for potential con-
founders, the adjusted hazard ratio was 1.57 (95% CI
1.2-2.3; P 5 .0006). Similarly the unadjusted hazard
ratio for NRM associated with AKI was 1.73 (95%
CI 1.0-3.0; P 5 .05), and after adjusting for the con-
founding variables it was 1.72 (95% CI 0.9-3.1;
P 5 .07). Among 303 patients previously not diag-
nosed with cGVHD, 166 developed clinically exten-
sive cGVHD. The adjusted hazards ratio for
312 C. R. Parikh et al.Table 1. Demographics and Transplant Characteristics of Study Patients
(Patients Surviving Beyond Day 100)
No AKI
(n 5 158)
AKI
(n 5 200) P
Patient sex
Female 47 (30%) 96 (48%)
Male 111 (70%) 104 (52%) .0005
Sex mismatch
No 75 (47%) 112 (56%)
Yes 83 (53%) 88 (44%) .11
Patient age
\50 years 58 (37%) 70 (35%) .74
$50 years 100 (63%) 130 (65%)
Diagnosis
ALL 7 (4%) 7 (3%)
AML 30 (19%) 40 (20%)
CLL 19 (12%) 21 (11%)
CML 8 (5%) 8 (4%)
HD 15 (9%) 17 (9%)
MDS 18 (11%) 21 (11%)
MM 31 (20%) 43 (22%)
NHL 28 (18%) 40 (20%)
Waldenstroms 2 (1%) 3 (1%) .87
Disease type
Indolent 78 (49%) 95 (48%)
Aggressive 80 (51%) 105 (53%) .73
HCT-comorbidity index (missing for 3 patients)
0 44 (28%) 55 (28%)
1,2 47 (30%) 66 (33%)
31 65 (42%) 78 (39%) .82
Baseline GFR
\30 3 (2%) 0
30-60 31 (20%) 16 (8%)
.60 124 (78%) 184 (92%) .0002 (#60 vs. .60)
Patient CMV status
Negative 81 (51%) 77 (39%)
Positive 77 (49%) 123 (62%) .02
Prior HCT
No 111 (70%) 150 (75%)
Auto/syngeneic 42 (27%) 45 (23%)
Allo 5 (3%) 5 (3%) .32 (No vs. Yes)
Stem cell source
BM 6 (4%) 1 (1%)
PBSC 152 (96%) 199 (100%) .03
Conditioning
TBI (200) 26 (16%) 56 (28%)
TBI (200) 1 Flu 132 (84%) 144 (72%) .01
Donor
Related 76 (48%) 122 (61%)
Unrelated 82 (52%) 78 (39%) .01
Acute GVHD (# day 100) (missing for 2 patients)
0/1 72 (46%) 74 (37%)
2 71 (45%) 97 (49%)
3-4 15 (9%) 27 (14%) .22
Chronic GVHD (# day 100)
No 139 (88%) 161 (81%)
Yes 19 (12%) 39 (20%) .06
ALL indicates acute lymphocytic leukemia; AML, acute myeloge-
nous leukemia; CLL, chronic lymphocytic leukemia; CML,
chronic myelogenous leukemia; HD, Hodgkin disease; MDS,
myelodysplastic syndrome; MM, multiple myeloma; NHL,
non-Hodgkin disease, HCT, hematopoetic cell transplantation;
GFR, glomerular filtration rate; BM, bone marrow; PBSC,
peripheral blood stem cells; TBI, total body irradiation; Flu, Flu-
darabine; GVHD, graft-versus-host disease.clinically extensive cGVHD associated with AKI was
1.42 (95% CI 1.0-2.0; P 5 .04).
DISCUSSION
Nonmyeloablative HCT is proving to be an
effective therapy for certain malignancies such as
low-grade lymphoma, chronic leukemias, acute mye-
logenous leukemia, acute lymphocytic leukemia
(ALL), (MM), myelodysplastic syndromes, and more
recently, autoimmune diseases and hemoglobinopa-
thies [21-23]. Moreover, it is the only form of HCT
that is available for patients who have contraindica-
tions to conventional HCTbecause of older age, organ
dysfunction, or previous myeloablative HCT. The
number of nonmyeloablative HCT procedures being
performed has increased many folds since the incep-
tion of the procedure in 1997 (www.ibmtr.org).
However, as nonmyeloablative HCT is a relatively
recent procedure, there are hardly any data related to
Figure 1. Association of AKI with long-term survival (relapse and
NRM). Patients with AKI have lower survival compared to patients
with no AKI (P\ .05).
Figure 2. Association of AKI with NRM. NRM in ‘‘AKI’’ group is
higher compared to patients who had no AKI throughout the study
period (P 5 .05).
AKI in nonmyeloablative HCT 313Table 2. Adjusted and Unadjusted Association of AKI with Overall Mortality, Nonrelapse Mortality, and Chronic GVHD
Overall mortality Nonrelapse mortality Chronic GVHD*
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Univariate (unadjusted)
AKI 1.42 (1.0-2.0) .03 1.73 (1.0-3.0) .05 1.58 (1.2-2.2) .004
Multivariate (adjusted)
AKI† 1.57 (1.1-2.2) .01 1.72 (0.9-3.1) .07 1.42 (1.0-2.0) .04
Female 0.75 (0.5-1.1) .11 0.95 (0.5-1.7) .86 0.89 (0.6-1.2) .51
Sex mismatch 1.30 (0.9-1.8) .12 1.41 (0.8-2.4) .21 0.97 (0.7-1.3) .84
HCT-comorbidity index 1,2 1.42 (0.9-2.3) .16 1.35 (0.6-3.1) .47 1.02 (0.7-1.5) .91
HCT-comorbidity index 31 2.38 (1.5-3.8) .0002 2.56 (1.2-5.7) .02 0.76 (0.5-1.1) .17
Aggressive disease 2.34 (1.6-3.4) \.0001 1.79 (1.0-3.1) .04 1.23 (0.9-1.7) .22
Bone marrow 0.77 (0.2-3.3) .72 1.08 (0.1-8.5) .94 0.40 (0.1-2.9) .37
Baseline GFR .60 1.24 (0.7-2.1) .43 0.73 (0.3-1.5) .41 1.49 (0.9-2.4) .10
CMV positive 1.17 (0.8-1.7) .37 1.85 (1.0-3.4) .05 1.07 (0.8-1.5) .69
Age $50 1.12 (0.8-1.6) .53 1.15 (0.6-2.1) .65 0.94 (0.7-1.3) .71
Unrelated donor 0.88 (0.6-1.3) .51 0.88 (0.5-1.6) .67 1.14 (0.8-1.7) .49
Fludarabine 1.47 (0.9-2.4) .13 1.40 (0.6-3.1) .41 0.76 (0.5-1.2) .20
Acute GVHD 31 2.56 (1.7-3.9) \.0001 4.46 (2.4-8.2) \.0001 0.97 (0.6-1.6) .92
Prior chronic GVHD 1.57 (0.5-1.2) .24 0.74 (0.4-1.5) .38 — —
HR indicates hazard ratio; AKI, acute kidney injury; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; CMV,
cytomegalovirus: GFR, glomerular filtration rate.
*Among 303 patients not previously diagnosed with chronic GVHD.
†Adjusted for sex, sex mismatch, age, disease type, HCT-comorbidity index, CKD, CMV, stem cell source, conditioning, donor type, prior acute
GVHD, prior chronic GVHD.long-term outcomes on acute complications such as
AKI after the procedure.
In this observational cohort study, we report the
long-term impact of AKI on mortality after nonmye-
loablative HCT. In our study the development of
AKI within the first 100 days after nonmyeloablative
HCT is associated with an increased overall mortality
by 57% on follow-up. In addition, the association of
AKI with NRM is even higher, contributing to 73%
increase in events after nonmyeloablative HCT. To
our knowledge, this is the first study that reports
long-term outcomes of AKI after 5 years following
nonmyeloablative HCT. Of interest is the finding
that only 13% of patients who developed AKI had per-
sistently elevated serum creatinine at day 100 and the
rest had their serum creatinine values close to 1.5 times
the baseline or lower. This brings out an important
point that probably the occurrence of AKI and its
incomplete structural and functional recovery itself
triggers some pathways that continue to lead to overall
mortality despite improvement in renal function.
The mechanism by which AKI, which is largely
clinically reversible, contributes to decreased long-
term survival is not entirely clear. In our previous study
we reported that 66% of the survivors had CKD at 1
year following nonmyeloablative HCT. CKD in this
study was defined as 25% decrease in GFR from base-
line after stopping calcineurin inhibitors. AKI was 1 of
the strongest risk factors for development of CKD, and
AKI was associated with a 32-fold increase in develop-
ment of CKD after adjusting for several other vari-
ables. In addition, 72% of patients had increasedblood pressure or were initiated on antihypertensive
medications on 1 year follow-up [9]. It is well known
that CKD is associated with increased overall mortal-
ity because of increased incidence of cardiovascular
disease [24]. Similarly, hypertension also accelerates
vascular disease and contributes to cardiovascular
and cerebrovascular morbidity and mortality. It is pos-
sible that the survivors of AKI after nonmyeloablative
HCT developed CKD and hypertension, thereby
contributing to their increased overall mortality.
However, we do not have serum creatinine values after
100 days or blood pressure readings to confirm the
hypothesis.
The increased mortality associated with AKI is not
solely because of the compromise in renal function.
AKI can contribute to other major organ dysfunction
such as lung and liver failure because of volume
overload, coagulation abnormalities, and increased
incidence of sepsis because of its alteration of leuko-
cyte function [25,26]. Cytokine or immune-mediated
damage to other organs from injured kidneys also
has been proposed as a mechanism for distant organ
injury seen [27]. The increased mortality in patients
with AKI can be explained by these physiologic and
immunologic functions that are deranged with AKI.
We have also demonstrated an increased association
of various organ toxicities after both myeloablative
and nonmyeloablative HCT in the setting of AKI.
There was a linear increase in other concomitant organ
toxicities like hepatic veno-occlusive disease and need
for mechanical ventilation with increasing severity of
AKI [14]. Thus, the distant effects of renal injury to
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functional damage to these nonrenal organs may also
contribute to poor outcomes in patients with AKI after
nonmyeloablative HCT. The causes of NRM in our
cohort were multiorgan failure, pulmonary complica-
tions, sepsis, gastrointestinal bleeding, and cardiac
dysfunction.
AKI can also contribute to increased treatment-
related (relapse) mortality by several mechanisms.
Development of AKI after nonmyeloablative HCT
may be detrimental as AKI interferes with dosing of
immunosuppressive drugs including methotrexate
(MTX) and the calcineurin inhibitors cyclosporine
and tacrolimus, and leads to the development of
GVHDand rejection. In our study, AKIwas associated
with an increased risk of developing clinically extensive
cGVHD. It is likely that the increase in overall mortal-
ity in patients who had AKI is because of the increased
incidence of cGVHD seen in this group.
Last, it is also possible that AKI does not contrib-
ute to mortality but is merely a surrogate of premature
mortality. AKI may occur in a sicker subset of patients
who are destined to have poor survival. However, the
baseline characteristics and the comorbidities of
patients with AKI did not significantly differ from
patients with no AKI. Additionally, in our study even
after adjusting for a comprehensive set of covariates,
AKI was associated with an increased risk of overall
mortality by over 50% at 5 years.
Changes in serum creatinine, especially those that
are minor and do not need any specific therapy, are
generally thought to be innocuous. However, even
small reversible changes in creatinine levels has been
shown to have an impact on overall short-term and
long-term outcomes after congestive heart failure
and cardiothoracic surgery [28,29]. AKI, regardless
of dialysis requirement, in critically ill patients has
also been linked with poor long-term survival in sev-
eral studies [10,12]. Thus, it is not very surprising
that AKI, which in most cases is reversible, is also asso-
ciated with increased overall long-term mortality in
nonmyeloablative HCT in our study. Our analysis
also revealed that occurrence of grade 2 AKI even
without the need for dialysis (as only 2 patients have
AKI requiring dialysis) is associated with higher over-
all mortality.
Although the present study is a unique opportunity
to study the long-term impact of AKI on overall
mortality, some limitations deserve mention. Because
this is an observational study, the study design may
not address all the potential confounders. The unmea-
sured confounders may have influenced our point
estimates. As mentioned earlier, we also do not have
follow-up information on renal function, cardiac func-
tion, and blood pressure. Similarly, we do not have
detailed information on the etiology of AKI, which
might also affect the long-term consequences of AKI,that is, benign causes like prerenal azotemia and
obstruction might have less long-term sequelae
compared to dense acute tubular necrosis because of
septic shock. Despite these limitations our study has
substantial strengths. It is the first detailed report of
the long-term burden of AKI after nonmyeloablative
HCT. The surveillance was rigorous with no patients
lost to follow-up. The data were prospectively col-
lected, and thus the reliability and validity of the data
were strong, with little to none missing data on most
of the variables. The size of the study cohort was big
enough for the study questions to be answered with
adequate statistical power.
In summary, patients who develop AKI have an
increased risk of mortality even if they do not require
dialysis and renal function reverses back to baseline.
The findings of this study call for further research
identifying preventative strategies in nonmyeloabla-
tive HCT for attenuating incidence and severity of
AKI. In addition, aggressive surveillance for diagnosis
and treatment of AKI sequelae such as CKD and hy-
pertension will be necessary to improve survival and
derive maximum benefit after the cure of malignancy.
Further studies with detailed longitudinal follow-up
in HCT patients to study the development of CKD,
hypertension, and other cardiovascular risk factors
will be necessary to accurately delineate the mecha-
nisms contributing to premature death in patients
who have been cured otherwise of their underlying
malignancy after the HCT procedure.
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